

E. Mateos Egido, A.M. Álamo Medina, M. Lombardero Pin, M.E Luján López, D. Fernández Vera. Pharmacy. Complejo Hospitalario Universitario Insular Materno Infantil. Las Palmas de Gran Canaria.

INTRODUCTION

- ✓ Neoadjuvant chemotherapy is the treatment of choice in locally advanced breast carcinoma.
- ✓ Pertuzumab is approved in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2 positive breast cancer

PURPOSE

- ✓ To evaluate the complete pathological response rate (pRC) obtained after therapy in combination with pertuzumab in our hospital

MATERIAL AND METHODS

- ✓ **Retrospective descriptive study**
- ✓ **Inclusion criteria:** patients with confirmed diagnosis of HER2 positive breast cancer in treatment with pertuzumab in combination with trastuzumab and taxanes as neoadjuvant treatment
- ✓ **Period:** Mars 2017-september 2018.
- ✓ **Efficacy endpoint:** complete pathological response (pCR) which is related to efficacy and with a longer long-term survival.
- ✓ **Safety:** adverse effects (AE) were collected for safety profile assessment.

RESULTS


Pacientes	n=28
Edad	50 años (rango 31-74)
Initial ECOG 0-1	100%
LVEF	61 % (mean)
Afectación axilar	89 %
Receptor Hormonal (+)	47%

Safety:

- ✓ **AE grade 1-2:** neurotoxicity, nausea and diarrhea
- ✓ No adverse events grade 3-4 were recorded

Efficacy:

- ✓ No adverse events grade 3-4 were recorded: 13 cases with pRC, in 3 patients there was a Miller and Payner grade 4 response and in one patient grade 3.
- ✓ The rest of the patients will have surgery soon.



CONCLUSIONES

- ✓ The data obtained so far are quite encouraging because of the good pRC rate obtained. We must take them with caution due to the low number of patients who have received treatment up to now. But this treatment is going to improve the prognosis of the disease with a tolerable toxicity profile.

